Pelacarsen to Lower Lp(a) After Recent Heart Attack
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether pelacarsen, an experimental medicine, can safely lower Lp(a)—a type of cholesterol linked to heart disease—in people who recently had a heart attack. The goal is to see if lowering Lp(a) can help prevent future heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a heart attack (STEMI or NSTEMI) within the past 10 days and were hospitalized for it
- Your Lp(a) blood level is 150 nmol/L or higher (a measure your doctor can check)
- Your blood pressure is controlled and stable on current treatment
- You do not have severe heart failure or a history of stroke or serious bleeding
- Your liver, kidneys, and blood platelet counts are working well enough
- You are not pregnant, nursing, or allergic to contrast dye used in heart imaging
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called pelacarsen for people with very high Lp(a) (a type of cholesterol) and existing heart or blood vessel disease. It aims to see if adding pelacarsen to your current cholesterol treatment can lower your Lp(a) levels further.
This study follows patients who completed an earlier pelacarsen trial to check if the treatment remains safe and well-tolerated over time. Pelacarsen is an experimental medicine being tested for heart and cholesterol health.
This trial is for people who have already finished taking pelacarsen in a previous study. It offers continued access to the drug and checks long-term safety.
This program provides access to pelacarsen (TQJ230) for patients with serious or life-threatening conditions who have no other treatment options and cannot join a clinical trial. It aims to offer potential benefit when standard therapies are not suitable.
This Phase 2 trial tests pelacarsen (TQJ230), a medication that lowers a blood fat called lipoprotein(a), to see if it slows progression of calcific aortic valve stenosis. It may help people whose valve narrowing is starting to become more severe, especially when their lipoprotein(a) level is high.
This trial tests whether the supplement L-carnitine, given during a heart attack procedure, can reduce heart muscle damage. If you are having a STEMI heart attack and are getting angioplasty, you may be able to join.
Hear when a new Acute Coronary Syndrome (ACS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.